Brief: SK bioscience and Hilleman Laboratories Announce Joint Development of Second-Generation Zaire Ebola Virus Vaccine
22/11/2023 13:04
Nov 22 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* SK BIOSCIENCE AND HILLEMAN LABORATORIES ANNOUNCE JOINT
DEVELOPMENT OF SECOND-GENERATION ZAIRE EBOLA VIRUS VACCINE
Source text for Eikon: ID:nPn1WkkLCa
Further company coverage: 302440.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine